Annual report pursuant to Section 13 and 15(d)

Segment Information (Tables)

v3.20.4
Segment Information (Tables)
12 Months Ended
Oct. 31, 2020
Segment Reporting [Abstract]  
Schedule of Segment Information

The following represents selected financial information for our segments for the years ended October 31, 2020 and 2019:

 

    Year Ended October 31,  
    2020     2019  
Net loss:                
CAR-T Therapeutics   $ (2,241,443 )   $ (5,074,868 )
Cancer Vaccines     (828,136 )     (677,450 )
Anti-Viral Therapeutics     (1,168,969 )     -  
Cancer Diagnostics     (5,836,594 )     (5,196,471 )
Patent Licensing     (17,221 )     (869,863 )
Total   $ (10,092,363 )   $ (11,818,652 )
                 
Total operating costs and expenses   $ 9,978,202     $ 12,140,005  
Less non-cash share-based compensation     (4,137,460 )     (5,713,746 )
Operating costs and expenses excluding non-cash share-based compensation   $ 5,840,742     $ 6,426,259  
                 
Operating costs and expenses excluding non-cash share based compensation:                
CAR-T Therapeutics   $ 1,141,542     $ 2,212,090  
Cancer Vaccines     365,681       458,392  
Anti-Viral Therapeutics     739,140       -  
Cancer Diagnostics     3,581,377       2,689,761  
Patent Licensing     13,002       1,066,016  
Total   $ 5,840,742     $ 6,426,259  

 

    October 31,  
    2020     2019  
Total assets:                
CAR-T Therapeutics   $ 2,988,124     $ 2,382,460  
Cancer Vaccines     946,923       489,881  
Anti-Viral Therapeutics     2,464,361       -  
Cancer Diagnostics     2,869,529       2,921,784  
Patent Licensing     184,027       499,568  
Total   $ 9,452,964     $ 6,293,693